From: Guillain-Barré syndrome AMSAN variant in a 90-year-old woman after COVID-19: a case report
Patient | Age | Sex | Comorbidity | GBS diagnosis | Additional Instrumental Diagnosis | Intercourse between COVID-19 infection and GBS symptoms (days) | IVIG administration | Outcome | |
---|---|---|---|---|---|---|---|---|---|
G.A.C. | 90 | F | Hypertension | Clinical, CSF, EMG | none | 30 | Yes | Death | |
Assini et al. [18] | 60 | M | None | Clinical, CSF, EMG | Antibody antiganglioside; SARS-CoV-2 in CSF | 20 | Yes | Persistent hyporeflexia; slight improvement in right foot drop | |
El Otmani [19] | 70 | F | Rheumatoid Arthritis | Clinical, CSF, EMG | SARS-CoV-2 in CSF | 3 | Yes | No neurological improvement | |
Mozhdehipanah [20] | 55 | F | COPD | Clinical, CSF, EMG | None | 26 | Yes | Death for ARDS after third day of IVG | |
Padroni et al. [21] | 70 | F | None | Clinical, CSF, EMG | None | 23 | Yes | Unknown | |
Sedaghat et al. [22] | 65 | M | Diabetes mellitus | Clinical, CSF, EMG | Cerebral and spinal MRI | 14 | Yes | Unknown | |
Toscano et al. [23] | 77 | F | hypertension, stroke, atrial fibrillation | Clinical, CSF, EMG | Antibody antiganglioside; SARS-CoV-2 in CSF; Cerebral and spinal MRI | 7 | Yes | No neurological improvement | |
Toscano et al. [23] | 23 | M | None | Clinical, CSF, EMG | Antibody antiganglioside; SARS-CoV-2 in CSF; Cerebral and spinal MRI | 10 | Yes | Neurological improvement of ataxia and facial weakness |